PolyPid Initiates Phase 3 Trial for P-14
Ticker: PYPD · Form: 6-K · Filed: Mar 31, 2026 · CIK: 0001611842
| Field | Detail |
|---|---|
| Company | Polypid Ltd. (PYPD) |
| Form Type | 6-K |
| Filed Date | Mar 31, 2026 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, phase-3, medical-devices
TL;DR
PolyPid starts Phase 3 trial for P-14, big step for SSI treatment.
AI Summary
On March 31, 2026, PolyPid Ltd. announced the initiation of a Phase 3 clinical trial for its lead product candidate, P-14, for the treatment of surgical site infections. The trial is expected to enroll approximately 400 patients across multiple sites.
Why It Matters
Successful completion of this Phase 3 trial could lead to regulatory approval for P-14, potentially offering a new treatment option for surgical site infections and impacting the company's future revenue.
Risk Assessment
Risk Level: medium — Phase 3 trials are critical but carry significant risk of failure, impacting the company's valuation and future prospects.
Key Numbers
- 400 — Patients (Number of patients expected to be enrolled in the Phase 3 trial)
Key Players & Entities
- PolyPid Ltd. (company) — Filer of the 6-K report and developer of P-14
- P-14 (product) — Lead product candidate for surgical site infections
- March 31, 2026 (date) — Date of the press release and filing
FAQ
What is the primary purpose of the Phase 3 clinical trial for P-14?
The Phase 3 clinical trial is designed to evaluate the efficacy and safety of P-14 for the treatment of surgical site infections.
When was the press release regarding the Phase 3 trial initiation issued?
The press release was issued on March 31, 2026.
What is the estimated number of patients to be enrolled in the Phase 3 trial?
Approximately 400 patients are expected to be enrolled in the Phase 3 trial.
What is the product candidate being tested in the Phase 3 trial?
The product candidate being tested is P-14.
What is the filing type and accession number for this SEC document?
This is a Form 6-K filing with SEC Accession No. 0001213900-26-036923.
Filing Stats: 293 words · 1 min read · ~1 pages · Grade level 8.9 · Accepted 2026-03-31 08:35:23
Filing Documents
- ea0284288-6k_polypid.htm (6-K) — 12KB
- ea028428801ex99-1.htm (EX-99.1) — 11KB
- ea028428801_ex99-1img1.jpg (GRAPHIC) — 2KB
- 0001213900-26-036923.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. POLYPID LTD. Date: March 31, 2026 By: /s/ Jonny Missulawin Name: Jonny Missulawin Title: Chief Financial Officer 3